CD19 and hematopoietic and lymphoid system neoplasm: iNKTs are also being tested against blood cancers, e.g., an anti-CD19 CAR-iNKT therapy for relapsed, refractory, high-risk B cell tumours is currently in phase I trials (NCT04814004) [167].